The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Horizon scan of T-cell lymphoma therapy
Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, comments on the future of upfront treatments for T-cell lymphomas, in particular highlighting a study of Pi3 kinase in the upfront setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Deepa Jagadeesh, MD, PhD, has received research funding from ADC Therapeutics, AstraZeneca, Debiopharm Group, MEI Pharma, Regeneron, Rhizen Pharma, Seagen, Trillium Therapeutics and LOXO Pharma.
